The dispute between generic drugmakers Apotex and Teva stemming from a former Teva executive’s alleged disclosure of trade secrets to an Apotex CEO while the two were dating is heating up, with the parties now sparring over the speed of discovery.
Shortly after Teva filed its lawsuit, which alleged its former senior director of regulatory affairs gave confidential information to Apotex CEO Jeremy Desai, Teva asked the U.S. District Court for the Eastern District of Pennsylvania to expedite discovery to determine the full extent of the information that was shared.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
